|
US6180371B1
(en)
*
|
1996-06-26 |
2001-01-30 |
Emory University |
Modified factor VIII
|
|
US5744446A
(en)
*
|
1992-04-07 |
1998-04-28 |
Emory University |
Hybrid human/animal factor VIII
|
|
US5663060A
(en)
*
|
1992-04-07 |
1997-09-02 |
Emory University |
Hybrid human/animal factor VIII
|
|
US5859204A
(en)
*
|
1992-04-07 |
1999-01-12 |
Emory University |
Modified factor VIII
|
|
US6376463B1
(en)
*
|
1992-04-07 |
2002-04-23 |
Emory University |
Modified factor VIII
|
|
US5888974A
(en)
*
|
1992-04-07 |
1999-03-30 |
Emory University |
Hybrid human/animal factor VIII
|
|
US5364771A
(en)
*
|
1992-04-07 |
1994-11-15 |
Emory University |
Hybrid human/porcine factor VIII
|
|
SE504074C2
(sv)
*
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
|
US5910481A
(en)
*
|
1995-11-13 |
1999-06-08 |
Immuno Ag |
Hybrid proteins with modified activity
|
|
DE19613620C2
(de)
*
|
1996-04-04 |
1998-04-16 |
Steag Micro Tech Gmbh |
Verfahren und Vorrichtung zum Trocknen von Substraten
|
|
US20040092442A1
(en)
*
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
US8183344B2
(en)
*
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
WO1997040145A1
(en)
*
|
1996-04-24 |
1997-10-30 |
The Regents Of The University Of Michigan |
Inactivation resistant factor viii
|
|
US7560107B2
(en)
*
|
1996-06-26 |
2009-07-14 |
Emory University |
Modified factor VIII
|
|
US6458563B1
(en)
*
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
|
US6200560B1
(en)
*
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
|
EP1144594A1
(de)
|
1998-11-24 |
2001-10-17 |
Regents Of The University Of Minnesota |
Transgenische zirkulierende endothelzellen
|
|
JP2005518181A
(ja)
|
2001-01-12 |
2005-06-23 |
ジ・アメリカン・ナショナル・レッド・クロス |
第viii因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
|
|
US20040143104A1
(en)
*
|
2001-08-08 |
2004-07-22 |
Wadsworth Samuel C. |
Methods of treating diabetes and other blood sugar disorders
|
|
EP1572885A2
(de)
*
|
2001-08-08 |
2005-09-14 |
Genzyme Corporation |
Verfahren zur behandlung von diabetes und anderer blutzuckerstörungen
|
|
PL2298347T3
(pl)
*
|
2003-05-06 |
2016-03-31 |
Bioverativ Therapeutics Inc |
Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
|
|
EP2345731B1
(de)
|
2003-09-30 |
2015-10-21 |
The Trustees of the University of Pennsylvania |
Adenoassoziierte Virus-Claden, Sequenzen, diese enthaltende Vektoren und ihre Verwendungen
|
|
US20050123997A1
(en)
*
|
2003-10-30 |
2005-06-09 |
Lollar John S. |
Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
|
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
|
US20050107318A1
(en)
*
|
2003-11-17 |
2005-05-19 |
Samuel Wadsworth |
Methods of treating diabetes and other blood sugar disorders
|
|
DK1750733T3
(da)
*
|
2004-05-03 |
2014-01-20 |
Univ Emory |
FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
|
|
ES2525067T3
(es)
|
2005-04-07 |
2014-12-17 |
The Trustees Of The University Of Pennsylvania |
Método de incremento de la función de un vector de AAV
|
|
CA2656558A1
(en)
*
|
2006-06-30 |
2008-01-10 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
|
CN102112144A
(zh)
*
|
2008-05-16 |
2011-06-29 |
拜耳医药保健有限公司 |
靶向性凝固因子及其使用方法
|
|
CA2771999A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
SI2506868T1
(en)
|
2009-12-06 |
2018-04-30 |
Bioverativ Therapeutics Inc. |
HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
WO2011126808A2
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
EP3508573A1
(de)
|
2010-07-09 |
2019-07-10 |
Bioverativ Therapeutics Inc. |
Systeme für faktor viii-verarbeitung und verfahren davon
|
|
DK2635297T3
(da)
|
2010-11-05 |
2019-05-06 |
Baxalta GmbH |
En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
|
|
TR201908020T4
(tr)
|
2011-02-17 |
2019-06-21 |
Univ Pennsylvania |
Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler.
|
|
US9486507B2
(en)
|
2011-06-10 |
2016-11-08 |
Biogen Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
PT3513804T
(pt)
*
|
2011-07-08 |
2022-06-02 |
Bioverativ Therapeutics Inc |
Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
|
|
WO2013016454A1
(en)
|
2011-07-25 |
2013-01-31 |
Biogen Idec Hemophilia Inc. |
Assays to monitor bleeding disorders
|
|
CN104271150A
(zh)
|
2012-01-12 |
2015-01-07 |
比奥根艾迪克Ma公司 |
嵌合因子viii多肽及其用途
|
|
EA038705B1
(ru)
|
2012-01-12 |
2021-10-07 |
Биовератив Терапьютикс Инк. |
Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
|
|
JP6256882B2
(ja)
|
2012-02-15 |
2018-01-10 |
アムニクス オペレーティング インコーポレイテッド |
第viii因子組成物、ならびに組成物の作製方法および用途
|
|
EP2822577B1
(de)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Rekombinante faktor-viii-proteine
|
|
CN104661674A
(zh)
|
2012-07-11 |
2015-05-27 |
阿穆尼克斯运营公司 |
具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
|
|
US10001495B2
(en)
|
2012-07-25 |
2018-06-19 |
Bioverativ Therapeutics Inc. |
Blood factor monitoring assay and uses thereof
|
|
HK1213767A1
(zh)
|
2012-10-18 |
2016-07-15 |
Bioverativ Therapeutics Inc. |
使用固定劑量凝血因子的方法
|
|
HK1214539A1
(zh)
|
2012-10-30 |
2016-07-29 |
Bioverativ Therapeutics Inc. |
應用viii因子多肽的方法
|
|
EP4122487A1
(de)
|
2013-03-15 |
2023-01-25 |
Bioverativ Therapeutics Inc. |
Faktor-viii-polypeptidformulierungen
|
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
|
CN113817069A
(zh)
|
2013-06-28 |
2021-12-21 |
比奥贝拉蒂治疗公司 |
具有xten的凝血酶可裂解连接子和其用途
|
|
WO2015021423A2
(en)
|
2013-08-08 |
2015-02-12 |
Biogen Idec Ma Inc. |
Purification of chimeric fviii molecules
|
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子viii-xten融合物及其用途
|
|
EP3065769A4
(de)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Prokoagulatorische fusionsverbindung
|
|
US10325687B2
(en)
|
2013-12-06 |
2019-06-18 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
|
AU2015204646B2
(en)
|
2014-01-10 |
2020-08-27 |
Bioverativ Therapeutics Inc. |
Factor VIII chimeric proteins and uses thereof
|
|
EP3283126B1
(de)
|
2015-04-16 |
2019-11-06 |
Emory University |
Rekombinante promotoren und vektoren zur proteinexpression in leber und verwendung davon
|
|
EA201890423A1
(ru)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
Слитые белки фактора ix, способы их получения и применения
|
|
BR112018012073A2
(pt)
|
2015-12-16 |
2018-11-27 |
Nz Inst Plant & Food Res Ltd |
métodos para produzir uma planta com pelo menos um fenótipo associado a nanismo e para identificar uma planta com um genótipo indicativo de pelo menos um fenótipo associado a nanismo, polinucleotídeo isolado, polipeptídeo arf3, construto, célula, planta, parte, propágulo ou progênie de uma planta.
|
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
|
JP2019536794A
(ja)
|
2016-12-02 |
2019-12-19 |
バイオベラティブ セラピューティクス インコーポレイテッド |
凝固因子に対する免疫寛容を誘導する方法
|
|
PL3793588T3
(pl)
|
2018-05-18 |
2025-09-01 |
Bioverativ Therapeutics Inc. |
Sposoby leczenia hemofilii a
|
|
JP7672334B2
(ja)
*
|
2018-10-23 |
2025-05-07 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア |
第viii因子機能を調節するための組成物および方法
|
|
WO2022032140A2
(en)
|
2020-08-07 |
2022-02-10 |
Amicus Therapeutics, Inc. |
Vesicle targeting proteins and uses of same
|
|
AU2023356318A1
(en)
|
2022-10-05 |
2025-05-08 |
Genxtraits, Inc. |
Uorf::reporter gene fusions to select sequence changes to gene edit into uorfs to regulate ascorbate genes
|